Nadja Vielot1, Michael G Hudgens, Nelly Mugo, Michael Chitwa, Joshua Kimani, Jennifer Smith. 1. From the Departments of *Epidemiology and †Biostatistics Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC; ‡Kenyatta National Hospital/University of Nairobi, Nairobi, Kenya; and §Lineberger Comprehensive Cancer Center, Chapel Hill, NC.
Abstract
BACKGROUND: Little is known about risk factors for persistent high-risk human papillomavirus (hrHPV) infection in low-income settings, and prior research has not quantified the relative duration of hrHPV infections stratified by risk factors. We compared the duration of hrHPV infection among female sex workers (FSWs) by exposure to sexually transmitted infections (STIs), using a highly sensitive biomarker assay. METHODS: From 2009 to 2011, 350 FSWs enrolled in this longitudinal study. Every 3 months, sociodemographic and sexual behavior data were collected via questionnaire, and APTIMA assays were used to detect the rRNA of Chlamydia trachomatis (CT), Neisseria gonorrhea, Trichomonas vaginalis, Mycoplasma genitalium, and messenger RNA of the E6/E7 oncoproteins expressed by hrHPV. Among 173 FSW who were infected with hrHPV during the observation period, accelerated failure time models estimated time ratios (TRs) for duration of hrHPV infection, comparing FSW infected with STIs at baseline to STI-uninfected FSWs. RESULTS: Median follow-up time was 26.2 months (interquartile range, 18.8-27.5 months). The median duration of hrHPV infection among all FSWs was 9.3 months (95% confidence interval [CI], 9.3-11.5). The duration of hrHPV infection among FSW infected with CT at baseline was greater than that among FSWs who were uninfected (adjusted TR, 1.7; 95% CI, 1.2-2.6). Among FSWs who were coinfected with hrHPV and CT at baseline, the adjusted TR was 3.4 (95% CI, 2.5-5.4) compared with FSWs infected with hrHPV only. No other STI was associated with hrHPV duration. CONCLUSIONS: Recent or concurrent CT infection was associated with prolonged hrHPV infection among a cohort of Nairobi FSWs. Management of CT could reduce risk for hrHPV persistence.
BACKGROUND: Little is known about risk factors for persistent high-risk human papillomavirus (hrHPV) infection in low-income settings, and prior research has not quantified the relative duration of hrHPV infections stratified by risk factors. We compared the duration of hrHPV infection among female sex workers (FSWs) by exposure to sexually transmitted infections (STIs), using a highly sensitive biomarker assay. METHODS: From 2009 to 2011, 350 FSWs enrolled in this longitudinal study. Every 3 months, sociodemographic and sexual behavior data were collected via questionnaire, and APTIMA assays were used to detect the rRNA of Chlamydia trachomatis (CT), Neisseria gonorrhea, Trichomonas vaginalis, Mycoplasma genitalium, and messenger RNA of the E6/E7 oncoproteins expressed by hrHPV. Among 173 FSW who were infected with hrHPV during the observation period, accelerated failure time models estimated time ratios (TRs) for duration of hrHPV infection, comparing FSW infected with STIs at baseline to STI-uninfected FSWs. RESULTS: Median follow-up time was 26.2 months (interquartile range, 18.8-27.5 months). The median duration of hrHPV infection among all FSWs was 9.3 months (95% confidence interval [CI], 9.3-11.5). The duration of hrHPV infection among FSW infected with CT at baseline was greater than that among FSWs who were uninfected (adjusted TR, 1.7; 95% CI, 1.2-2.6). Among FSWs who were coinfected with hrHPV and CT at baseline, the adjusted TR was 3.4 (95% CI, 2.5-5.4) compared with FSWs infected with hrHPV only. No other STI was associated with hrHPV duration. CONCLUSIONS: Recent or concurrent CTinfection was associated with prolonged hrHPV infection among a cohort of Nairobi FSWs. Management of CT could reduce risk for hrHPV persistence.
Authors: Jill E Koshiol; Jane C Schroeder; Denise J Jamieson; Stephen W Marshall; Ann Duerr; Charles M Heilig; Keerti V Shah; Robert S Klein; Susan Cu-Uvin; Paula Schuman; David Celentano; Jennifer S Smith Journal: Int J Cancer Date: 2006-10-01 Impact factor: 7.396
Authors: Anne F Rositch; Anne E Burke; Raphael P Viscidi; Michelle I Silver; Kathryn Chang; Patti E Gravitt Journal: Cancer Res Date: 2012-09-27 Impact factor: 12.701
Authors: Rui-Rui Peng; Hong-Min Li; Helena Chang; Jian-Hong Li; Alberta L Wang; Xiang-Sheng Chen Journal: Sex Health Date: 2012-05 Impact factor: 2.706
Authors: Jie Ting; Nelly Mugo; Jessie Kwatampora; Craig Hill; Michael Chitwa; Suha Patel; Hannah Gakure; Joshua Kimani; Victor J Schoenbach; Charles Poole; Jennifer S Smith Journal: Sex Transm Dis Date: 2013-07 Impact factor: 2.830
Authors: Maria Inês Rosa; Jandira M G Fachel; Daniela D Rosa; Lidia R Medeiros; Cristine N Igansi; Mary C Bozzetti Journal: Am J Obstet Gynecol Date: 2008-09-16 Impact factor: 8.661
Authors: Jill Koshiol; Lisa Lindsay; Jeanne M Pimenta; Charles Poole; David Jenkins; Jennifer S Smith Journal: Am J Epidemiol Date: 2008-05-15 Impact factor: 4.897
Authors: Jennifer E Cameron; Anne F Rositch; Nadja A Vielot; Nelly R Mugo; Jessie K L Kwatampora; Wairimu Waweru; Aubrey E Gilliland; Michael E Hagensee; Jennifer S Smith Journal: Sex Transm Dis Date: 2018-10 Impact factor: 2.830
Authors: Jenny C McCloskey; W Martin Kast; James P Flexman; Dugald McCallum; Martyn A French; Michael Phillips Journal: Papillomavirus Res Date: 2017-11-07
Authors: Pierre P M Thomas; Jay Yadav; Rajiv Kant; Elena Ambrosino; Smita Srivastava; Gurpreet Batra; Arvind Dayal; Nidhi Masih; Akash Pandey; Saurav Saha; Roel Heijmans; Jonathan A Lal; Servaas A Morré Journal: Microorganisms Date: 2019-11-12
Authors: Frances H Ampt; Lisa Willenberg; Paul A Agius; Matthew Chersich; Stanley Luchters; Megan S C Lim Journal: BMJ Open Date: 2018-09-17 Impact factor: 2.692